These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9384935)

  • 1. Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete?
    Goff DC
    Harv Rev Psychiatry; 1995; 3(2):101-3. PubMed ID: 9384935
    [No Abstract]   [Full Text] [Related]  

  • 2. [Risperidone].
    Zolk O; Thürauf N
    Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
    [No Abstract]   [Full Text] [Related]  

  • 3. [Risperidon--contribution to an integrated therapy of schizophrenia. Yearly session of the German Society for Psychiatry, Psychotherapy and Neurology. Düsseldorf, 17 September 1996].
    Fortschr Neurol Psychiatr; 1996 Dec; 64(12 Suppl):1-4. PubMed ID: 9131062
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-benefits of risperidone.
    Bilsker D
    Psychiatr Serv; 1996 Mar; 47(3):309-10. PubMed ID: 8820560
    [No Abstract]   [Full Text] [Related]  

  • 5. [The new antipsychotic preparation Rispolept (risperidone)].
    Iakovlev VA
    Voen Med Zh; 1999 Nov; 320(11):43-5. PubMed ID: 10650767
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
    Annemans L
    Pharmacoeconomics; 2005; 23 Suppl 1():1-2. PubMed ID: 16416757
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 8. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefits of new drugs.
    Daniel DG; Moseley C; Rosenfield S; Wolf S; Nawroz S
    Psychiatr Serv; 1995 Aug; 46(8):835-6. PubMed ID: 7583490
    [No Abstract]   [Full Text] [Related]  

  • 10. Risperidone treatment of tardive dyskinesia and dystonia.
    Chong SA; Remington G; Tan CH
    J Clin Psychiatry; 1999 May; 60(5):340-1. PubMed ID: 10362448
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 12. Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.
    Yoshida K; Higuchi H; Hishikawa Y
    Clin Neuropharmacol; 1998; 21(1):68-9. PubMed ID: 9579290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
    Haycox A
    Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 15. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
    Clewell JD; Baker RW
    Value Health; 2005; 8(2):175-6. PubMed ID: 15804326
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
    Amin S
    Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone-induced mania.
    Zolezzi M; Badr MG
    Ann Pharmacother; 1999 Mar; 33(3):380-1. PubMed ID: 10200867
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current pharmacotherapy of schizophrenia].
    Bitter I
    Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.